CMS Issues Proposed Rule to Cover ‘Breakthrough’ Medical Devices

News
Published on:
August 11, 2020

The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule this week that would give breakthrough medical devices national Medicare coverage on the same day they receive FDA approval for four years. The proposed rule, called Medicare Coverage of Innovative Technology (MCIT), would establish a Medicare coverage pathway that provides beneficiaries nationwide with faster access to new, innovative medical devices designated as ‘breakthrough’ by the Food and Drug Administration (FDA).

During the four year timeframe, CMS recommends that manufacturers develop additional evidence showing the applicability of their products to Medicare beneficiaries so they can apply for further coverage.

Before the MCIT, after a breakthrough technology receives FDA approval, an often lengthy and costly process for Medicare coverage begins. That period has been challenging for companies because innovators spent time and resources to achieve FDA approval, only to need to spend more time and money to acquire Medicare coverage. This lag time is not only costly but has also reduced access to innovative technologies by senior populations.

This proposed rule follows up on creating a pathway to Medicare coverage the same day as FDA market authorization for breakthrough devices. The proposal will be live from September 1, 2020 and open for comment till October 30, 2020. Additionally, the proposed rule would allow Medicare to cover eligible breakthrough devices the FDA has approved for use in 2019 or 2020.

What does it mean for you?

Organizations will need to understand the details of the breakthrough designation and how it applies to their innovation before proceeding. Moreover, what evidence needs to be generated in these four years to maintain coverage. The Alira Health team can help you understand how this designation applies to you, and how you can best leverage the proposed rule for your innovation.

For more information, please contact Deepak Sahu.

Click here to see the proposed rule from The Department of Health and Human Services.

Related news

Multimedia September 29, 2022
Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Events September 7, 2022
MDIC Annual Patient Forum 2022
We are pleased to share that we will be joining as speakers MDIC Annual Patient Forum 2022 – a key platform for the discussion of how to transform patient engagement throughout the(...)
Clinical Trials MedTech Patient Engagement
Events August 31, 2022
BIOMEDevice 2022
We are excited to share that we will be joining BIOMEDevice 2022 as speakers! This event will bring engineers, business leaders, disruptive companies, and innovative thinkers from the(...)
Investor Relations Medical Devices MedTech
Multimedia August 29, 2022
Webinar Replay: Clinical Trial Management in MedTech & Working with CROs
As a MedTech company, understanding clinical trial management is critical, and working with CROs is part of the journey. Join the webinar to learn about this crucial topic.
Clinical Trial Management CRO MedTech
Events August 23, 2022
MedtechVision 2022
Join us at the MedtechWomen MedtechVision Conference, where we will be presenting a state of the Medtech Industry Report with an overview of the innovation and advancement and much more.
Diagnotics MedTech Patient Centricity
Publications August 4, 2022
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
MedTech Regulatory
Publications July 15, 2022
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.
Real-World Evidence Registry-based studies Regulatory RWE
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.